Price Performance & Valuation Year to date, GSK’s stock has gained 4.8% compared to the industry’s 20.0% growth. The stock has also underperformed the sector and the S&P 500.

Shares of GSK fell to below $30 around the time of the demerger, but have since recovered to about $36. The 20% gain over 34 ...

GSK and S&P 500 Performance During 2007-08 Crisis GSK stock declined from $53 in September 2007 (pre-crisis peak) to around $28 in March 2009, as the markets bottomed out, implying it lost 48% of ...

GSK’s Price Performance, Valuation & Estimate Movement GSK stock has risen 20.1% year to date compared with an increase of 4.0% for the industry.

The latest trading session saw GSK (GSK) ending at $36.19, denoting a -0.85% adjustment from its last day's close. The stock outperformed the S&P 500, which registered a daily loss of 1.47% ...

GSK is a Zacks Rank #3 (Hold) stock, with a Value Style Score of A and VGM Score of A. Shares are currently trading at a forward P/E of 8.6X for the current fiscal year compared to the Medical ...

GlaxoSmithKline Is Moving Forward After Woeful Performance Jul. 08, 2014 5:27 PM ET GSK plc (GSK) Stock AZN, MRK, NVS PFE INVA GSK 8 Comments Options Calling 480 Follower s ...

GSK GSK stock has risen 21.5% in the past six months. The consistently strong performance of the Specialty Medicines unit, regulatory and pipeline successes and an optimistic outlook for the long ...